mTOR activation is a biomarker and a central pathway to autoimmune disorders, cancer, obesity, and aging

Rapamycin doses sufficient to extend lifespan do not compromise muscle mitochondrial content or endurance

(2016) Lan Ye et al.   Aging-US

Comprehensive metabolome analyses reveal N-acetylcysteine-responsive accumulation of kynurenine in systemic lupus erythematosus: implications for activation of the mechanistic target of rapamycin

(2015) Andras Perl et al.   Metabolomics

PTENtiating autoimmunity through Treg cell deregulation

(2015) John P Ray et al.   NATURE IMMUNOLOGY

Treg cells require the phosphatase PTEN to restrain TH1 and TFH cell responses

(2015) Sharad Shrestha et al.   NATURE IMMUNOLOGY

Normalization of CD4 + T cell metabolism reverses lupus

(2015) Yiming Yin et al.   Science Translational Medicine

Current treatment strategies for inhibiting mTOR in cancer

(2015) Francesca Chiarini et al.   TRENDS IN PHARMACOLOGICAL SCIENCES

Glycerol-3-phosphate acyltransferase-4-deficient mice are protected from diet-induced insulin resistance by the enhanced association of mTOR and rictor

(2014) Chongben Zhang et al.   AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM

Increased Mitochondrial Electron Transport Chain Activity at Complex I Is Regulated by N-Acetylcysteine in Lymphocytes of Patients with Systemic Lupus Erythematosus

(2014) Edward Doherty et al.   ANTIOXIDANTS & REDOX SIGNALING

Remote Control of Gene Function by Local Translation

(2014) Hosung Jung et al.   CELL

Improving Type 2 Diabetes Through a Distinct Adrenergic Signaling Pathway Involving mTORC2 That Mediates Glucose Uptake in Skeletal Muscle

(2014) M. Sato et al.   DIABETES

Sirt2 Deacetylase Is a Novel AKT Binding Partner Critical for AKT Activation by Insulin

(2014) Gopalakrishnan Ramakrishnan et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Metabolic programming and PDHK1 control CD4+ T cell subsets and inflammation

(2014) Valerie A. Gerriets et al.   JOURNAL OF CLINICAL INVESTIGATION

Estradiol and mTORC2 cooperate to enhance prostaglandin biosynthesis and tumorigenesis in TSC2-deficient LAM cells

(2014) Chenggang Li et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Mechanistic Target of Rapamycin Complex 1 Expands Th17 and IL-4+ CD4-CD8- Double-Negative T Cells and Contracts Regulatory T Cells in Systemic Lupus Erythematosus

(2014) H. Kato et al.   JOURNAL OF IMMUNOLOGY

Requirement of Mammalian Target of Rapamycin Complex 1 Downstream Effectors in Cued Fear Memory Reconsolidation and Its Persistence

(2014) T. N. Huynh et al.   JOURNAL OF NEUROSCIENCE

Inhibition of the mTORC Pathway in the Antiphospholipid Syndrome

(2014) Guillaume Canaud et al.   NEW ENGLAND JOURNAL OF MEDICINE

p53 suppresses carcinoma progression by inhibiting mTOR pathway activation

(2014) N Akeno et al.   ONCOGENE

Treatment-related fatigue with everolimus and temsirolimus in patients with cancer—a meta-analysis of clinical trials

(2014) Ling Peng et al.   TUMOR BIOLOGY

Longevity pathways and memory aging

(2014) Ilias Gkikas et al.   Frontiers in Genetics

Rapamycin-mediated lifespan increase in mice is dose and sex dependent and metabolically distinct from dietary restriction

(2013) Richard A. Miller et al.   AGING CELL

HRES-1/Rab4-mediated depletion of Drp1 impairs mitochondrial homeostasis and represents a target for treatment in SLE

(2013) Tiffany N Caza et al.   ANNALS OF THE RHEUMATIC DISEASES

SIRT1 Limits the Function and Fate of Myeloid-Derived Suppressor Cells in Tumors by Orchestrating HIF-1 -Dependent Glycolysis

(2013) G. Liu et al.   CANCER RESEARCH

Duration of Rapamycin Treatment Has Differential Effects on Metabolism in Mice

(2013) Yimin Fang et al.   Cell Metabolism

mTOR complex 2 mediates Akt phosphorylation that requires PKCε in adult cardiac muscle cells

(2013) Phillip C. Moschella et al.   CELLULAR SIGNALLING

Mechanistic Target of Rapamycin Complex 2 Protects the Heart From Ischemic Damage

(2013) Mirko Völkers et al.   CIRCULATION

mTOR complex 2 phosphorylates IMP1 cotranslationally to promote IGF2 production and the proliferation of mouse embryonic fibroblasts

(2013) N. Dai et al.   GENES & DEVELOPMENT

Metabolic control of the Treg/Th17 axis

(2013) Joseph Barbi et al.   IMMUNOLOGICAL REVIEWS

Tuberous Sclerosis and Fulminant Lupus in a Young Woman

(2013) Namrata Singh et al.   JCR-JOURNAL OF CLINICAL RHEUMATOLOGY

Regulation of mTORC1 and its impact on gene expression at a glance

(2013) M. Laplante et al.   JOURNAL OF CELL SCIENCE

HIF-1 mediates metabolic responses to intratumoral hypoxia and oncogenic mutations

(2013) Gregg L. Semenza   JOURNAL OF CLINICAL INVESTIGATION

Mechanistic Target of Rapamycin Activation Triggers IL-4 Production and Necrotic Death of Double-Negative T Cells in Patients with Systemic Lupus Erythematosus

(2013) Z.-W. Lai et al.   JOURNAL OF IMMUNOLOGY

Potent Dual Inhibitors of TORC1 and TORC2 Complexes (KU-0063794 and KU-0068650) Demonstrate In Vitro and Ex Vivo Anti-Keloid Scar Activity

(2013) Farhatullah Syed et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

Sin1 phosphorylation impairs mTORC2 complex integrity and inhibits downstream Akt signalling to suppress tumorigenesis

(2013) Pengda Liu et al.   NATURE CELL BIOLOGY

mTOR inhibits autophagy by controlling ULK1 ubiquitylation, self-association and function through AMBRA1 and TRAF6

(2013) Francesca Nazio et al.   NATURE CELL BIOLOGY

Regulatory T cell proliferative potential is impaired in human autoimmune disease

(2013) Fortunata Carbone et al.   NATURE MEDICINE

Oxidative stress in the pathology and treatment of systemic lupus erythematosus

(2013) Andras Perl   Nature Reviews Rheumatology

Drug-Eluting Coronary-Artery Stents

(2013) Giulio G. Stefanini et al.   NEW ENGLAND JOURNAL OF MEDICINE

The Pathogenesis of the Antiphospholipid Syndrome

(2013) Bill Giannakopoulos et al.   NEW ENGLAND JOURNAL OF MEDICINE

Ribosomal protein S6 kinase activity controls the ribosome biogenesis transcriptional program

(2013) C Chauvin et al.   ONCOGENE

Mechanism-Based Treatment in Tuberous Sclerosis Complex

(2013) Kristina Jülich et al.   PEDIATRIC NEUROLOGY

Rapamycin Reverses Status Epilepticus-Induced Memory Deficits and Dendritic Damage

(2013) Amy L. Brewster et al.   PLoS One

Incidence and Risk of Treatment-Related Mortality with mTOR Inhibitors Everolimus and Temsirolimus in Cancer Patients: A Meta-Analysis

(2013) Wei-Xiang Qi et al.   PLoS One

Stimulation of de Novo Pyrimidine Synthesis by Growth Signaling Through mTOR and S6K1

(2013) I. Ben-Sahra et al.   SCIENCE

A Tumor Suppressor Complex with GAP Activity for the Rag GTPases That Signal Amino Acid Sufficiency to mTORC1

(2013) L. Bar-Peled et al.   SCIENCE

Matched and mismatched metabolic fuels in lymphocyte function

(2013) Alfredo Caro-Maldonado et al.   SEMINARS IN IMMUNOLOGY

Phase I safety, pharmacokinetic, and pharmacodynamic study of the oral phosphatidylinositol-3-kinase and mTOR inhibitor BGT226 in patients with advanced solid tumors

(2012) B. Markman et al.   ANNALS OF ONCOLOGY

Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus

(2012) Michelle Petri et al.   ARTHRITIS AND RHEUMATISM

N-acetylcysteine reduces disease activity by blocking mammalian target of rapamycin in T cells from systemic lupus erythematosus patients: A randomized, double-blind, placebo-controlled trial

(2012) Zhi-Wei Lai et al.   ARTHRITIS AND RHEUMATISM

Hepatic mTORC2 Activates Glycolysis and Lipogenesis through Akt, Glucokinase, and SREBP1c

(2012) Asami Hagiwara et al.   Cell Metabolism

Evaluating Oxidative Stress in Human Cardiovascular Disease: Methodological Aspects and Considerations

(2012) R. Lee et al.   CURRENT MEDICINAL CHEMISTRY

Structure-Activity Analysis of Niclosamide Reveals Potential Role for Cytoplasmic pH in Control of Mammalian Target of Rapamycin Complex 1 (mTORC1) Signaling

(2012) Bruno D. Fonseca et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

PDK1 regulation of mTOR and hypoxia-inducible factor 1 integrate metabolism and migration of CD8+T cells

(2012) David K. Finlay et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Rapamycin-Induced Insulin Resistance Is Mediated by mTORC2 Loss and Uncoupled from Longevity

(2012) D. W. Lamming et al.   SCIENCE

Rapid non-genomic signalling by 17β-oestradiol through c-Src involves mTOR-dependent expression of HIF-1α in breast cancer cells

(2011) S Sudhagar et al.   BRITISH JOURNAL OF CANCER

Activation of mTORC2 by Association with the Ribosome

(2011) Vittoria Zinzalla et al.   CELL

Control of TH17/Treg Balance by Hypoxia-Inducible Factor 1

(2011) Eric V. Dang et al.   CELL

ATP-Competitive Inhibitors of mTOR: An Update

(2011) S. Schenone et al.   CURRENT MEDICINAL CHEMISTRY

Rapamycin-sensitive signals control TCR/CD28-drivenIfng,Il4andFoxp3transcription and promoter region methylation

(2011) Romana Tomasoni et al.   EUROPEAN JOURNAL OF IMMUNOLOGY

The Transcription Factor Myc Controls Metabolic Reprogramming upon T Lymphocyte Activation

(2011) Ruoning Wang et al.   IMMUNITY

Redox Regulates Mammalian Target of Rapamycin Complex 1 (mTORC1) Activity by Modulating the TSC1/TSC2-Rheb GTPase Pathway

(2011) Sei Yoshida et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

An analysis of the metabolic syndrome phenotype in systemic lupus erythematosus

(2011) B Parker et al.   LUPUS

The AMPK signalling pathway coordinates cell growth, autophagy and metabolism

(2011) Maria M. Mihaylova et al.   NATURE CELL BIOLOGY

The kinase mTOR regulates the differentiation of helper T cells through the selective activation of signaling by mTORC1 and mTORC2

(2011) Greg M Delgoffe et al.   NATURE IMMUNOLOGY

Systemic Lupus Erythematosus

(2011) George C. Tsokos   NEW ENGLAND JOURNAL OF MEDICINE

Efficacy and Safety of Sirolimus in Lymphangioleiomyomatosis

(2011) Francis X. McCormack et al.   NEW ENGLAND JOURNAL OF MEDICINE

PIK3CA mutation, but not PTEN loss of function, determines the sensitivity of breast cancer cells to mTOR inhibitory drugs

(2011) B Weigelt et al.   ONCOGENE

Mammalian target of rapamycin up-regulation of pyruvate kinase isoenzyme type M2 is critical for aerobic glycolysis and tumor growth

(2011) Q. Sun et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Oxidative stress, inflammation and carcinogenesis are controlled through the pentose phosphate pathway by transaldolase

(2011) Andras Perl et al.   TRENDS IN MOLECULAR MEDICINE

Abnormalities of T cell signaling in systemic lupus erythematosus

(2011) Vaishali R Moulton et al.   ARTHRITIS RESEARCH & THERAPY

Autoimmune-mediated reduction of high-density lipoprotein-cholesterol and paraoxonase 1 activity in systemic lupus erythematosus-prone gld mice

(2010) Roshni Srivastava et al.   ARTHRITIS AND RHEUMATISM

Activity of the Novel Dual Phosphatidylinositol 3-Kinase/Mammalian Target of Rapamycin Inhibitor NVP-BEZ235 against T-Cell Acute Lymphoblastic Leukemia

(2010) F. Chiarini et al.   CANCER RESEARCH

Chronic Rapamycin Treatment Causes Glucose Intolerance and Hyperlipidemia by Upregulating Hepatic Gluconeogenesis and Impairing Lipid Deposition in Adipose Tissue

(2010) V. P. Houde et al.   DIABETES

Rapamycin inhibits relapsing experimental autoimmune encephalomyelitis by both effector and regulatory T cells modulation

(2010) Marianna Esposito et al.   JOURNAL OF NEUROIMMUNOLOGY

Metabolic syndrome in patients with systemic lupus erythematosus: association with traditional risk factors for coronary heart disease and lupus characteristics

(2010) R. Telles et al.   LUPUS

Laboratory markers of cardiovascular risk in pediatric SLE: the APPLE baseline cohort

(2010) SP Ardoin et al.   LUPUS

Activation of a Metabolic Gene Regulatory Network Downstream of mTOR Complex 1

(2010) Katrin Düvel et al.   MOLECULAR CELL

Long-term Administration of Rapamycin Reduces Adiposity, but Impairs Glucose Tolerance in High-Fat Diet-fed KK/HlJ Mice

(2009) Geng-Ruei Chang et al.   BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY

Dissecting the role of mTOR: Lessons from mTOR inhibitors

(2009) Ryan J.O. Dowling et al.   BIOCHIMICA ET BIOPHYSICA ACTA-PROTEINS AND PROTEOMICS

mTOR Complex 2 Is Required for the Development of Prostate Cancer Induced by Pten Loss in Mice

(2009) David A. Guertin et al.   CANCER CELL

AZD8055 Is a Potent, Selective, and Orally Bioavailable ATP-Competitive Mammalian Target of Rapamycin Kinase Inhibitor with In vitro and In vivo Antitumor Activity

(2009) C. M. Chresta et al.   CANCER RESEARCH

An ATP-competitive Mammalian Target of Rapamycin Inhibitor Reveals Rapamycin-resistant Functions of mTORC1

(2009) Carson C. Thoreen et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Prevention of hepatocarcinogenesis and increased susceptibility to acetaminophen-induced liver failure in transaldolase-deficient mice by N-acetylcysteine

(2009) Robert Hanczko et al.   JOURNAL OF CLINICAL INVESTIGATION

Activation of Mammalian Target of Rapamycin Controls the Loss of TCR  in Lupus T Cells through HRES-1/Rab4-Regulated Lysosomal Degradation

(2009) D. R. Fernandez et al.   JOURNAL OF IMMUNOLOGY

Rapamycin Protects Against High Fat Diet–Induced Obesity in C57BL/6J Mice

(2009) Geng-Ruei Chang et al.   JOURNAL OF PHARMACOLOGICAL SCIENCES

mTORC1-Activated S6K1 Phosphorylates Rictor on Threonine 1135 and Regulates mTORC2 Signaling

(2009) L.-A. Julien et al.   MOLECULAR AND CELLULAR BIOLOGY

mTOR regulates memory CD8 T-cell differentiation

(2009) Koichi Araki et al.   NATURE

mTOR Regulation and Therapeutic Rejuvenation of Aging Hematopoietic Stem Cells

(2009) C. Chen et al.   Science Signaling

mTOR Inhibition by Rapamycin Prevents  -Cell Adaptation to Hyperglycemia and Exacerbates the Metabolic State in Type 2 Diabetes

(2008) M. Fraenkel et al.   DIABETES

Differential Dependence of Hypoxia-inducible Factors 1α and 2α on mTORC1 and mTORC2

(2008) Alfredo Toschi et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Reversal of learning deficits in a Tsc2 +/− mouse model of tuberous sclerosis

(2008) Dan Ehninger et al.   NATURE MEDICINE

Systemic lupus erythematosus and “lupus dyslipoproteinemia”

(2007) Jozélio Freire de Carvalho et al.   AUTOIMMUNITY REVIEWS